CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02616 CSTONE PHARMA-B

Closed 03-27 16:08:20

8.330

+1.430

+20.72%

High8.470	Low6.780	Vol76.36M
Open6.800	D1 Closing6.900	Amplitude24.49%
Mkt Cap12.30B	Tradable Cap12.30B	Total Shares1.48B
T/O613.53M	T/O Rate5.17%	Tradable Shares1.48B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"CSTONE PHARMA-B","latestPrice":8.33,"timestamp":1774598900003,"preClose":6.9,"halted":0,"volume":76364971,"delay":0,"changeRate":0.20724637681159416,"floatShares":1476000000,"shares":1476000000,"eps":-0.08094718492200904,"marketStatus":"Closed","change":1.43,"latestTime":"03-27 16:08:20","open":6.8,"high":8.47,"low":6.78,"amount":613527186,"amplitude":0.244928,"askPrice":8.33,"askSize":20000,"bidPrice":8.32,"bidSize":55500,"shortable":3,"etf":0,"ttmEps":-0.33053141241587863,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":5,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":6.9,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"volumeRatio":3.945122,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"2622181426","title":"CStone Pharmaceuticals' Loss Widens in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2622181426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622181426?lang=en_us&edition=fundamental","pubTime":"2026-03-27 12:30","pubTimestamp":1774585858,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals  booked a loss of 437 million yuan in 2025, widening from 91.2 million yuan a year earlier, according to a Thursday Hong Kong bourse filing.Shares of the pharmaceutical firm were up nearly 18% in late Friday morning trade.Loss per share came in at 0.31 yuan, compared with 0.07 yuan a year earlier.Revenue fell 34% to 269.6 million yuan from 407.2 million yuan.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"1135867297","title":"CStone Pharmaceuticals-B Surges Over 20% by Late Morning on Strong CS2009 Lung Cancer Efficacy Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1135867297","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135867297?lang=en_us&edition=fundamental","pubTime":"2026-03-27 11:50","pubTimestamp":1774583426,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) saw its gains expand to over 20% by late morning. At the time of writing, the stock was up 20.29%, trading at HK$8.30, with a turnover of HK$390 million. The company...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"1184614767","title":"CSTONE PHARMA-B (02616) Surges Over 20% on Strong CS2009 Lung Cancer Efficacy Data; First Phase III Global Trials Expected This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1184614767","media":"Stock News","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184614767?lang=en_us&edition=fundamental","pubTime":"2026-03-27 11:32","pubTimestamp":1774582341,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) saw its gains expand beyond 20%. At the time of writing, the stock was up 19.42% to HK$8.24, with a turnover of HK$377 million. The surge follows the company's announcement of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","III","BK1574","BK4588","BK4585","BK4134","02616","VXUS"],"gpt_icon":0},{"id":"1134940401","title":"Stock Track | CStone Pharma Soars 5.51% Intraday on Strong 2025 Results and Promising Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1134940401","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134940401?lang=en_us&edition=fundamental","pubTime":"2026-03-27 09:39","pubTimestamp":1774575550,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals' stock surged 5.51% during intraday trading on Friday, following the release of its 2025 annual results which highlighted significant strategic and clinical advancements.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02616"],"gpt_icon":0},{"id":"2622247863","title":"Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2622247863","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622247863?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:32","pubTimestamp":1774531920,"startTime":"0","endTime":"0","summary":"-- The global, multicenter Phase I/II clinical trial of CS2009. Australia and China, and the Phase II IND application has been approved. in the US. CS2009 demonstrates an excellent safety profile with a >=Grade. 3 TRAE rate of 23%, along with broad-spectrum anti-tumor activity.Notably, monotherapy data in lung cancer are encouraging: in first-line. NSCLC patients with PD-L1 TPS >=50%, the ORR reached 90% with a DCR of. 100%, while the ORR was 25% in IO-pretreated NSCLC .Furthermore, significant benefits were observed in patients with heavily. pre-treated \"cold tumors,\" achieving an ORR of 40% in non-clear cell. renal cell carcinoma  and 33.3% in soft tissue sarcoma .-- The global Phase Ib multicenter trial of CS5001  is being. advanced rapidly and efficiently in Australia and China, with its R&D. progress ranking among the top two globally. In combination with R-CHOP. rate exceeds 90%, and the ORR reaches 100%. Additionally, the combination. complementing its successful NRDL renewal at","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1161","BK4156","CC","LU2211817866.USD","R","BK4213","IE00BYQQ9H92.USD","BK4181","BK1574","LU2487616109.SGD","BK4121","PD","ORR","LU1169589451.USD","PK","LU0210528500.USD","BK4218","LU2413666699.HKD","BK4023","BK4007","BK4585","BK4006","BK4567","LU1721428933.USD","LU0053666078.USD","LU0456854461.SGD","IE00BFXG0V08.USD","IE00B5TLWC47.USD","LU1093756168.USD","BK4533","LU0266512127.USD","CRC","BK4232","BK4107","LU0347712357.USD","MTD","HCC","LU1093756325.SGD","PROC","02616","L","LU2413666426.HKD","BK4098","BK4548","BK4022","LU1169590202.USD"],"gpt_icon":0},{"id":"2622850657","title":"CStone Pharmaceuticals -  Loss for the Year Was RMB437.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850657","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850657?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:43","pubTimestamp":1774529020,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0JB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2622850658","title":"CStone Pharmaceuticals FY2025; revenue drops 33.8% to RMB 270 million due to lower licensing fees","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850658?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:43","pubTimestamp":1774529009,"startTime":"0","endTime":"0","summary":"CStone reported expanded international regulatory approvals for sugemalimab in the EU and the UK, adding an additional indication in III-stage NSCLC.The company also signed commercialization agreements for sugemalimab covering 10 Latin American countries and 23 Western European countries plus the UK.CStone said it has established partnerships that extend sugemalimab’s international reach to more than 60 countries.In China, pralsetinib was added to the national reimbursement drug list effective January 1, 2026, which the company expects to support future demand.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service ope","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL24Pm23:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"1104410716","title":"CStone reports 90% ORR in first-line NSCLC for trispecific antibody CS2009; Phase III global trials slated for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1104410716","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104410716?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:23","pubTimestamp":1774517028,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (CStone) released a voluntary update on the clinical progress of its self-developed trispecific antibody CS2009 (PD-1/VEGF/CTLA-4), highlighting an improved safety profile,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"gpt_icon":0},{"id":"1189079157","title":"CStone Pharmaceuticals-B Unveils Latest Clinical Progress and Phase I/II Key Data for Trispecific Antibody CS2009","url":"https://stock-news.laohu8.com/highlight/detail?id=1189079157","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189079157?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:21","pubTimestamp":1774516865,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) has announced the latest clinical progress for its internally developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009. The data demonstrate an excellent safety...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1169590202.USD","BK4023","02616","LU1169589451.USD","BK1574","BK1161"],"gpt_icon":0},{"id":"2622307678","title":"CStone Pharmaceuticals reports CS2009 Phase I safety; Grade ≥3 TRAEs rise to 23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622307678","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622307678?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:01","pubTimestamp":1774515690,"startTime":"0","endTime":"0","summary":"CStone reported updated Phase I/II clinical progress for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, from ongoing trials in Australia and China.As of mid-March 2026, Phase I enrolled 113 patients with advanced solid tumors and reported a 23% incidence of Grade ≥3 treatment-related adverse events.In Phase II first-line NSCLC with PD-L1 TPS ≥50%, CS2009 monotherapy showed a 90% overall response rate and a 100% disease control rate.The company said updated Phase I and Phase II data are expected to be presented at the 2026 ASCO Annual Meeting and/or the 2026 ESMO Congress.CStone plans to initiate Phase III global multi-regional clinical trials for CS2009 by the end of 2026 in indications including NSCLC and colorectal cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL70Wbzt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2622278830","title":"CStone Pharmaceuticals reports CS2009 Phase I/II progress; ORR rises to 90% in first-line NSCLC with PD-L1 TPS≥50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622278830","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622278830?lang=en_us&edition=fundamental","pubTime":"2026-03-26 17:01","pubTimestamp":1774515681,"startTime":"0","endTime":"0","summary":"CStone reported new development progress for CS2009, positioning the program as a potential differentiated entrant in immuno-oncology by combining multiple established targets into a single drug candidate.The company said it plans to start its first global Phase 3 multi-regional clinical trials by the end of 2026, initially targeting non-small cell lung cancer, colorectal cancer, and small cell lung cancer.CStone disclosed that 113 patients had been enrolled in the Phase 1 study as of mid-March 2026, supporting continued advancement of the asset into later-stage development.The company also said additional Phase 1 and Phase 2 data are expected to be presented in 2026 at major oncology conferences, which could influence partnering and competitive positioning.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL72mNTQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"1163282057","title":"CSTONE PHARMA-B Shares Extend Gains Following Top ESMO Guideline Recommendation for Core Product","url":"https://stock-news.laohu8.com/highlight/detail?id=1163282057","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163282057?lang=en_us&edition=fundamental","pubTime":"2026-03-26 10:58","pubTimestamp":1774493905,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) saw its shares rise more than 4% again. At the time of writing, the stock was up 3.77% to HK$7.14, with a turnover of HK$35.6465 million. The movement follows an announcement...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02616","VXUS","BK4588","BK1574","BK4585"],"gpt_icon":0},{"id":"1172230908","title":"CStone Pharmaceuticals' Sugemalimab Receives ESMO Guideline Recommendation for Stage III NSCLC Consolidation Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1172230908","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172230908?lang=en_us&edition=fundamental","pubTime":"2026-03-25 17:24","pubTimestamp":1774430687,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) announced that its core commercial product, sugemalimab, has received a [I, A] grade recommendation in the European Society for Medical Oncology (ESMO) guidelines....","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","III","02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2622029921","title":"CStone Pharmaceuticals’ sugemalimab gains ESMO I,A recommendation; consolidation treatment duration rises to 24 months for stage III NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2622029921","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622029921?lang=en_us&edition=fundamental","pubTime":"2026-03-25 17:16","pubTimestamp":1774430181,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals’ sugemalimab gains ESMO I,A recommendation; consolidation treatment duration rises to 24 months for stage III NSCLC. Sugemalimab gained an ESMO guideline recommendation at level [I, A] for consolidation treatment in stage III non-small cell lung cancer, a milestone that could strengthen its positioning against established immuno-oncology options in Europe.The update adds Sugemalimab to ESMO’s “Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline,” which may support market access momentum across the EU and other markets.ESMO’s recommendation specifies use for eligible stage III NSCLC patients after concurrent or sequential chemoradiotherapy, with treatment duration capped at no more than 24 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL5g6JRt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"1152835973","title":"CSTONE PHARMA-B Shares Climb Over 4% on Triple Pipeline Recognition at Prestigious Cancer Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1152835973","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152835973?lang=en_us&edition=fundamental","pubTime":"2026-03-24 10:24","pubTimestamp":1774319068,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million. The increase follows recent news that the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1161","BK4585","VXUS","02616","BK1574"],"gpt_icon":0},{"id":"1172787493","title":"CSTONE PHARMA-B to Present Three Self-Developed Pipeline Findings at Prestigious Global Oncology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1172787493","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172787493?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:20","pubTimestamp":1773789619,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) announced that preclinical research findings from three of its internally developed drug pipelines have been selected for poster presentation at the 2026 American Association...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"1153215896","title":"CStone Pharma-B (02616 HK) to Showcase Three Novel ADC Candidates at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1153215896","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153215896?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:42","pubTimestamp":1773787345,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (CStone Pharma-B, 02616 HK) announced that preclinical data for three proprietary antibody-drug conjugates (ADCs)—CS5007, CS5008 and CS5006—have been accepted for poster...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616"],"gpt_icon":0},{"id":"2620540981","title":"CStone Pharmaceuticals to present preclinical data for three pipeline assets at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620540981","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620540981?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:29","pubTimestamp":1773786580,"startTime":"0","endTime":"0","summary":"CStone will attend the 2026 American Association for Cancer Research  Annual Meeting on April 17-22, 2026, at the San Diego Convention Center in California. The company said it will present three preclinical poster presentations on April 20, 2026, from 9:00 AM to 12:00 PM PT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLc8LQY9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2618247642","title":"CStone Pharmaceuticals (SEHK:2616) Valuation Check After New UK Approval For Sugemalimab In Stage III Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618247642","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618247642?lang=en_us&edition=fundamental","pubTime":"2026-03-09 14:25","pubTimestamp":1773037547,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (SEHK:2616) is back on investors radar after the UK regulator granted a new indication for its cancer drug sugemalimab, extending its use in specific stage III lung cancer patients.\nSee our latest analysis for CStone Pharmaceuticals.\nThe MHRA decision lands at a time when CStone’s 1 month share price return of 30.91% and 90 day share price return of 18.75% suggest building momentum. However, the 1 year total shareholder return of 100.30% contrasts with a 5 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-check-after-new-uk","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-check-after-new-uk","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SSI","02616","III","BK1161","BK4134","BK1574","DCF"],"gpt_icon":0},{"id":"1135152718","title":"CSTONE PHARMA-B Shares Surge Over 9% Following FTSE China Inclusion and Progress in Triple Antibody Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1135152718","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135152718?lang=en_us&edition=fundamental","pubTime":"2026-03-06 11:59","pubTimestamp":1772769544,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) rose more than 9% again. At the time of writing, the stock was up 9.18% to HK$7.02, with a turnover of HK$70.8136 million. On the news front, according to the semi-annual...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TWM","BK4581","BK4614","BK1574","MNQmain","IWO","IWN","SRTY","02616","BK4550","BK1161","TZA","BK4534","UWM","RWM","BK4585","BK4588","BK4535"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":0.0849},{"period":"3month","weight":0.2191},{"period":"6month","weight":-0.0738},{"period":"1year","weight":1.0117},{"period":"ytd","weight":0.3093}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":-0.0652},{"period":"3month","weight":-0.0373},{"period":"6month","weight":-0.0487},{"period":"1year","weight":0.0585},{"period":"ytd","weight":-0.0302}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CStone Pharmaceuticals is an investment holding company primarily engaged in the research and development of therapies for oncology, autoimmune and inflammation, and other key disease areas. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, the sales of pharmaceutical products, as well as the provision of license of its intellectual property (IP) or commercialization license. The Company’s products primarily include targeted therapies, AYVAKIT (avapritinib), GAVRETO (pralsetinib) and CEJEMLY (sugemalimab). The Company is also engaged in the development and commercialization of immuno-oncology. The Company primarily conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":-0.050688},{"month":2,"riseRate":0.428571,"avgChangeRate":0.069097},{"month":3,"riseRate":0.25,"avgChangeRate":-0.087566},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.048094},{"month":5,"riseRate":0.5,"avgChangeRate":0.100514},{"month":6,"riseRate":0.714286,"avgChangeRate":0.09443},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05639},{"month":8,"riseRate":0.428571,"avgChangeRate":0.079119},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.071005},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.012196},{"month":11,"riseRate":0.571429,"avgChangeRate":0.010396},{"month":12,"riseRate":0.428571,"avgChangeRate":0.004524}],"exchange":"SEHK","name":"CSTONE PHARMA-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CSTONE PHARMA-B(02616) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CSTONE PHARMA-B,02616,CSTONE PHARMA-B股票,CSTONE PHARMA-B股票老虎,CSTONE PHARMA-B股票老虎国际,CSTONE PHARMA-B行情,CSTONE PHARMA-B股票行情,CSTONE PHARMA-B股价,CSTONE PHARMA-B股市,CSTONE PHARMA-B股票价格,CSTONE PHARMA-B股票交易,CSTONE PHARMA-B股票购买,CSTONE PHARMA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CSTONE PHARMA-B(02616),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CSTONE PHARMA-B(02616) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}